New Study Highlights Promising Pathway to Sustainable Vaccines and Biologics Manufacturing in Africa

New Study Highlights Promising Pathway to Sustainable Vaccines and Biologics Manufacturing in Africa, using a Contract Manufacturing Model for Fill & Finish Operations.

6 JULY 2023 – Unizima, the technical advisory arm of Univercells Group, announces the findings of a new costing simulation tool that shows that local vaccine manufacturing can be sustainable in Africa under certain conditions.

As Africa’s population is projected to double by 2050 to 2.4 billion people1, meaning 1 in 4 people will be African by the middle of the century, the continent is focused on building a pharmaceutical sector of its own to respond to the needs of its population and secure high skilled jobs and economic growth on the continent. Looking at the African public vaccines market, it is projected to grow from USD 1.3 billion annually to between USD 2.4 and 5.4 billion by 2030, meaning a fourfold increase in less than 10 years 2.

This includes vaccines alone, not considering the need for other sterile injectable medicines such as for diabetes care (insulin) or cancer treatment (monoclonal antibodies).